|
Ronald D. Henriksen joined Cytori Therapeutics as Director in October 2002 and was previously a Board member of its predecessor, StemSource, Inc. Mr. Henriksen has more than 30 years of experience in healthcare, pharmaceutical, biotechnology and consulting and venture capital industries. He currently serves as Chief Investment Officer of Twilight Ventures, LLC, and Chairman of the Board of Semafore Pharmaceuticals and EndGenitor Technologies, of which he is also Founder and President. For more than 20 years, Mr. Henriksen held executive positions with Eli Lilly, where he served as Managing Director for Brazil, Mexico and Central America, and negotiated international contracts through Lilly Business Development. Additional Board Directorships include board member positions of PreMD, Inc., and BioStorage Technologies. Mr. Henriksen received his B.S. in Industrial Administration from Iowa State University and an M.B.A. with distinction from Harvard Business School. He also served as an officer for four years in the U.S. Navy. | 